Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of mavacamten丨cas 1642288-47-8 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
|
Appearance |
White solid |
|
Purity |
99% min |
|
Identification |
IR, HPLC |
|
Polymorph |
Form A |
|
Water |
0.5% max |
|
Specific rotation |
-25° to -45.0° (C=4mg/ml, Methanol) |
|
Microbial Limit - TAMC |
30 CFU/g max |
|
Microbial Limit - TYMC |
10 CFU/g max |
|
Single impurity |
0.2% max |
|
Total impurities |
1.0% max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2934999099305 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: -20 °C |
|
Condition to Avoid |
|
|
Package |
Manufacturing Information
|
Parameter |
Specification |
|
Capacity |
1MT/year |
|
Frequency |
|
|
Main Export Countries |
|
|
Capacity/Batch |
|
|
Experience |
Production since 2022 |
|
Stock |
Introduction
Mavacamten丨CAS 1642288-47-8, is a first-in-class, selective cardiac myosin inhibitor developed for the treatment of hypertrophic cardiomyopathy (HCM). It represents a breakthrough in cardiovascular medicine by directly targeting the underlying biomechanical cause of HCM, a condition characterized by abnormal thickening of the heart muscle, particularly the left ventricle. Mavacamten was approved by the U.S. FDA under the brand name Camzyos.
Applications
A. Obstructive Hypertrophic Cardiomyopathy (oHCM)
The primary approved indication for mavacamten is symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
In patients with oHCM, mavacamten significantly reduces LVOT gradients, improves exercise capacity, and alleviates symptoms such as dyspnea, chest pain, and fatigue.
Approved for use in adults NYHA class II–III with obstructive HCM.
B. Non-Obstructive HCM and Other Cardiac Conditions (Investigational)
Mavacamten is also under investigation for:
Non-obstructive HCM: A subset of patients with thickened myocardium without outflow tract obstruction.
Heart failure with preserved ejection fraction (HFpEF): Potential utility due to its ability to improve diastolic function.
Diastolic dysfunction associated with other cardiomyopathies.
Benefits
A. Disease-Modifying Therapy
Unlike conventional HCM therapies that target symptoms, Mavacamten丨CAS 1642288-47-8 modifies the pathophysiology of the disease by addressing hypercontractility at the sarcomeric level.
Potential to slow or reverse disease progression, especially when used early.
B. Improvement in Clinical Outcomes
In pivotal clinical trials (e.g., EXPLORER-HCM), mavacamten significantly improved:
Exercise tolerance (VO₂ max)
NYHA functional class
Quality of life scores (KCCQ, MLWHFQ)
Reduced need for invasive procedures like surgical myectomy or alcohol septal ablation.
C. Oral Administration
Administered orally once daily, offering ease of use compared to invasive interventions or complex medication regimens.
D. Reversible Effects
The effects of mavacamten are dose-dependent and reversible, allowing for careful titration and monitoring based on echocardiographic and clinical response.
Conclusion
Mavacamten丨CAS 1642288-47-8 is a novel, selective cardiac myosin inhibitor that directly addresses the underlying cause of obstructive hypertrophic cardiomyopathy. Its ability to reduce myocardial hypercontractility, improve functional status, and potentially modify disease progression marks it as a groundbreaking therapy in cardiology. While careful monitoring is essential due to its potent negative inotropic effect, mavacamten offers a new standard of care for patients with HCM and holds promise for future applications in broader cardiac conditions.
